Prognostic value of urinary prostate cancer antigen 3 (PCA3) during active surveillance of patients with low-risk prostate cancer receiving 5α-reductase inhibitors-Reference-Cited by-同舟云学术

Prognostic value of urinary prostate cancer antigen 3 (PCA3) during active surveillance of patients with low-risk prostate cancer receiving 5α-reductase inhibitors

Published:2017-10-25 Issue:3 Volume:121 Page:399-404
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:BJU Int

Author:

Fradet Vincent¹^ORCID,Toren Paul¹^ORCID,Nguile-Makao Molière¹,Lodde Michele¹,Lévesque Jérome¹,Léger Caroline¹,Caron André¹,Bergeron Alain¹,Ben-Zvi Tal¹,Lacombe Louis¹,Pouliot Frédéric¹,Tiguert Rabi¹,Dujardin Thierry¹,Fradet Yves¹

Affiliation:

1. Centre Hospitalier Universitaire de Québec-Université Laval; Québec QC Canada

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bju.14041/fullpdf

Reference37 articles.

1. Active surveillance for low-risk prostate cancer-an evolving international standard of care;Cooperberg;JAMA Oncol,2017

2. Novel tools to improve patient selection and monitoring on active surveillance for low-risk prostate cancer: a systematic review;Bergh;Eur Urol,2014

3. Active surveillance for prostate cancer: a narrative review of clinical guidelines;Bruinsma;Nat Rev Urol,2016